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Abstract: We conducted this systematic review and meta-analysis of prospective studies to determine
the effect of probiotic administration on serum C-reactive protein (CRP) concentrations. We searched
PubMed-Medline, Web of Science, the Cochrane, and Google Scholar databases (until May 2016)
to identify prospective studies evaluating the impact of probiotic administration on CRP. We used
a random effects models and generic inverse variance methods to synthesize quantitative data,
followed by a leave-one-out method for sensitivity analysis. The systematic review registration
number was: CRD42016039457. From a total of 425 entries identified via searches, 20 studies
were included in the final analysis. The meta-analysis indicated a significant reduction in serum
CRP following probiotic administration with a weighted mean difference (WMD) of −1.35 mg/L,
(95% confidence interval (CI) −2.15 to −0.55, I2 65.1%). The WMDs for interleukin 10 (IL10) was
−1.65 pg/dL, (95% CI −3.45 to 0.14, I2 3.1%), and −0.45 pg/mL, (95% CI −1.38 to 0.48, I2 10.2%)
for tumor necrosis factor alpha (TNF-α). These findings were robust in sensitivity analyses.
This meta-analysis suggests that probiotic administration may significantly reduce serum CRP
while having no significant effect on serum IL10 and TNF-α.
Keywords: meta-analysis; probiotic; C-reactive protein
1. Introduction
Probiotics have been described as ‘live microorganisms which, when administered in adequate
amounts, have a health benefit on the host’ [1,2] through their impact on the intestinal tract.
Probiotics are now extensively consumed in the form of fermented milk products such as yogurt
or as a freeze-dried culture [3–5]. The main probiotic bacteria related to dairy products include
Lactobacillus acidophilus, Lactobacillus casei, and Bifidobacteria [2,4]. It is suggested that probiotics not
only improve the balance of gut microbiota in favor of the healthy bacteria but are also helpful
in either preventing or improving the outcomes of a number of health conditions such as obesity,
insulin resistance, type 2 diabetes, and non-alcoholic fatty liver disease [6,7]. Some beneficial effects
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of probiotics include modulation of intestinal microbiota, strengthening of the epithelial barrier,
and immunomodulation [8].
Serum C-reactive protein (CRP) is a marker of systemic inflammation, and is elevated in
the presence of chronic conditions, including cardiovascular diseases (CVD) [9,10], obesity [11],
type 2 diabetes [12], and several components of the metabolic syndrome [10,13], including high
blood pressure [14], high waist circumference [15], fasting blood glucose [16–18], low serum
high-density lipoprotein cholesterol, and raised triacylglycerol [19]. The anti-inflammatory properties
of some strains of probiotics are thought to act by reducing mucosal inflammation via modulation
of cytokine levels, and other inflammatory mediators are reported in some in vitro and in vivo
studies [6,20]. Studies suggest the consumption of probiotic yogurt containing L. acidophilus and
Bifidobacterium animalis in pregnant women for nine weeks led to a reduction in serum high sensitivity
(hs)-CRP as the same probiotic supplementation in colorectal cancer, autoimmune, and chronic kidney
disease [21–23]. The decreased inflammation and oxidative stress due to probiotics might be due to
their effects on increasing glutathione (GSH) levels and scavenging superoxide and hydroxyl radicals,
decreasing the expression of interleukin-6 (IL-6) in adipocytes, and decreasing adiposity [24,25].
However, some studies have reported a non-significant effect of probiotic supplementation on serum
hs-CRP level [22,26]. Moreover, there are limitations of the existing studies such as small sample size,
issues with research design, and subject traits (gender, ethnicity, age, etc.). These problems limit the
ability to draw reliable conclusions. On the other hand, dietary supplementation with probiotics can
have different effects on some indices of inflammatory and anti-inflammatory indexes. Meta-analysis
may overcome these limitations by increasing the effective sample size. Hence, the present study
aimed to resolve the uncertainty about the impact of probiotics on serum hs-CRP as an indicator
of inflammation by systematically reviewing the literature and performing meta-analysis of all
randomized control trials investigating the effects of probiotic supplementation on serum hs-CRP
levels as one of the measures of inflammation related to disease outcome.
2. Materials and Methods
2.1. Literature Search Strategy
We designed the present study according to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) Guidelines [27–29]. We registered the study
protocol with the International Prospective Register of Systematic Reviews, PROSPERO
(registration No. CRD42016039457). The primary exposure of interest was probiotic administration
while the primary outcome of interest was changes in CRP levels subsequent to probiotic
administration. We also evaluated the impact of probiotics on interleukin 10 (IL10), tumor necrosis
factor alpha (TNF-α), interleukin 1β (IL1β), serum triglycerides (TG), serum total cholesterol
(TC), serum high density lipoproteins (HDL), serum low density lipoproteins (LDL), and fasting
blood glucose (FBG). We searched multiple databases, including PUBMED/Medline, Cochrane
Central Register of Controlled Trials (CCTR), Cochrane Database of Systematic Reviews (CDSR),
MEDLINE and Web of Science, until May 2016 using a combination of search terms available in the
Supplementary Materials Table S1. The wild-card term ‘*’ was used to increase the sensitivity of the
search strategy. No language restriction was applied. We hand searched the reference list of qualified
articles and conducted email correspondence with authors for additional data where relevant.
2.2. Selection Criteria
We included all randomized control trials (RCTs) studies evaluating the effect of probiotic
supplementation on the outcome of interest. The inclusion criteria were as follows: (1) a controlled
trial with either parallel or crossover design; (2) presentation of satisfactory information on primary
outcome at baseline and at the end of follow-up in each group or the net change values; (3) prospective
studies of patients treated with probiotic supplementation compared to a control group (either no
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probiotic supplementation or placebo). Exclusion criteria were as follows: (i) non-clinical studies;
(ii) observational studies with case–control, cross-sectional or cohort design; and (iii) studies that did
not provide mean (or median) plasma concentrations of the outcomes of interest at baseline and/or
the end of the trial. We also excluded narrative reviews, papers in a language other than English,
comments, opinion pieces, methodological papers, editorials, letters, or any other publications lacking
primary data and/or explicit method descriptions. Duplicate studies were removed by a screening
of titles and abstracts by two reviewers. To prevent potential bias, the reviewers were blinded to the
names, qualifications, and institutional affiliations of the study authors. The agreement between the
reviewers was excellent (Kappa index: 0.88; p < 0.001). Disagreements were resolved at a meeting
between reviewers prior to the selected articles being retrieved (Figure 1).
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Figure 1. Pref rred Reporting Items for ie s and Meta-Analy es (PRISMA) flow chart
for the selection of studies. CRP, C-reactive protein; RCT, randomized control trial.
2.3. Data Extraction and Management
The full text of studies meeting the inclusion criteria was retrieved and screened to determine
eligibility by two reviewers (MohsenMazidi, Peyman Rezaie). Following assessment of methodological
quality, the two reviewers extracted data using a purpose-designed data extraction form and
independently summarized what they considered to be the most outstanding results from each
study. These summaries were compared and any differences of opinion resolved by discussion and
consultation with a third reviewer. Any further necessary calculations on study data were conducted
by the first reviewer and checked by the second reviewer. Descriptive data extracted included the
first author’s name, reference, country, study design, probiotics, delivery method, duration (weeks),
age (years), type of CRP assay used, background disease and sample size.
2.4. Quality Assessment
We used the Cochrane criteria to systematically assess bias in the eligible RCTs [30]. The items
used for the assessment of each study were (i) adequacy of random sequence generation; (ii) allocation
concealment; (iii) blinding of participants; (iv) personnel and outcome assessment; (v) handling of
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drop-outs (incomplete outcome data); (vi) selective outcome reporting; and (vii) other potential sources
of bias. A judgment of ‘yes’ indicated low risk of bias, while ‘no’ indicated a high risk of bias, taking
into account the recommendations of the Cochrane Handbook. We labeled uncertain or unknown risk
of bias as “unclear”.
2.5. Data Synthesis
Following the recommendation of the Cochrane Handbook, to calculate the effect size, we used
the mean change from baseline to the end point in the concentrations and standard deviation (SD)
of the variables of interest for both control and intervention groups [30,31]. In brief, we calculated
the net changes in measurements (change scores) as the measure at the end of follow-up −measure
at baseline. For RCTs, change scores were calculated as (measure at the end of follow-up in the
treatment group −measure at baseline in the treatment group) − (measure at the end of follow-up
in the control group − measure at baseline in the control group). We used the following formula
to calculate standard deviation (SD) in situations where only the standard error of the mean (SEM)
was available: SD = SEM × square root (n), where n is the number of subjects [17]. If the outcome
measures were reported in median and range (or 95% confidence interval (CI)), we estimated the
mean and standard SD values using the method described by Hozo et al. [32]. Blood lipid and glucose
levels were collated in mmol/L; a multiplication factor of 0.0259, 0.0113, or 0.0555 was used to convert
cholesterol (total cholesterol, HDL-C or LDL-C), triglycerides and glucose levels respectively from
mg/dL to mmol/L as appropriate [17].
We used a random effects model (using the DerSimonian–Laird method) and the generic inverse
variance method to compensate for the heterogeneity of studies regarding demographic characteristics
of populations being studied [33,34]. Heterogeneity was quantitatively assessed using an I2 index.
I2 values <50% and ≥50% corresponded with the use of a fixed-effects or random-effects model,
respectively. Effect sizes are expressed as the weighted mean difference (WMD) and 95% confidence
interval (CI). To determine the influence of each study on the overall effect size, a sensitivity analysis
was conducted using the leave-one-out method (i.e., removing one study each time and repeating the
analysis). The sensitivity analysis involved repeating the meta-analysis and substituting alternative
decisions or ranges of values for decisions that were arbitrary or unclear [35–37].
2.6. Publication Bias
We visually inspected the Begg’s funnel plot asymmetry, Begg’s rank correlation, and Egger’s
weighted regression tests to evaluate the potential publication bias [18]. This step was followed by
adjusting the analysis for the effects of publication bias using the Duval & Tweedie ‘trim and fill’
and ‘fail-safe N’ methods [38]. We conducted the meta-analysis using Comprehensive Meta-Analysis
(CMA) V3 software (Biostat, Englewood, NJ, USA) [17,39].
3. Results
3.1. Summary of Searches and Study Selection Process
We identified a total of 425 citations, of which 326 records remained after removing duplicates.
After screening via titles and abstracts, 49 articles remained for further evaluation, of which 29 were
excluded for the following reasons: non-human studies, genetic, or molecular studies (n = 15);
reviews or editorial articles (n = 5); or short follow-up duration (n = 9); see Figure 1. Finally, 20 studies
met all inclusion criteria for the meta-analysis. All these studies were in English. We found five studies
in non-English languages. These studies were excluded at the first step of the study selection procedure.
3.2. Risk of Bias Assessment
There was a lack of information about blinding of outcome assessment (n = 2) and blinding
of participants and personnel (n = 2); however, all evaluated studies had a low risk of bias
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according to selective outcome reporting. Details of the quality of bias assessment are shown in
Supplementary Materials Table S2.
3.3. Characteristics of the Eligible Studies
The characteristics of the included studies are summarized in Table 1. These studies were
published between 2003 and 2015 from fifteen countries including Iran (four studies),
India (three studies), Finland (two studies), and one study from each of the following countries:
the United States of America, Denmark, New Zealand, Austria, Sweden, Canada, Turkey, Norway,
China, Spain, and one multi-country study. Participants in two studies were only females [6,40],
while the proportion of men in other studies ranged from 9% [40] to 95% [41]. The mean age of
participants fluctuated from 6 months [42] to 85 years [43]. The duration of follow-up across studies
ranged from 7 days [42,44] to 6 months [45]. A nasogastric tube was used as a method of delivery
of probiotic in two studies [44,46] while the other studies used oral supplementation as the method
of delivery.
3.4. Pooled Estimate of the Effect of Probiotic Administration on CRP
The pooled estimate (weighted mean difference) of the effect of probiotic administration on CRP
levels was −1.35 mg/L, (95% CI −2.15 to −0.55, I2 65.1%) across all studies (Figure 2).
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Figure 2. Forest plot displaying weighted mean difference and 95% confidence intervals for the impact
of probiotic administration on C-reactive protein (CRP) levels.
Results on the effect of probiotic administration on the other inflammatory, anti-inflammatory,
lipid profile, and glycemia measurements are presented in Table 2.
3.5. Sensitivity Analysis
In leave-one-out sensitivity analyses, the pooled effect estimates remained similar across all
studies which confirm that the significant difference between the studied groups is the overall effect
of all included studies. Analysis showed that if we only pool the studies with the enzyme-linked
immunosorbent assay (ELISA) method (CRP measurement), the heterogeneity is reduced to 52.1%.
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Table 1. General characteristics of the studies included in meta-analysis.
First Author,
Reference
Country
Total Sample
Size (% Female)
Study Design Probiotics Features
Delivery
Method
Duration
(Weeks)
Age (Years)
C-reactive Protein
(CRP) Assay
Background
Disease
Sample Size
Alipour B, 2014 [6] Iran 44 (100%)
Randomized, double-blind,
placebo-controlled trial,
108 colony forming units (CFU) of
L. casei 01 and maltodextrin
Orally 8 weeks
Test: 44.29;
Control: 41.14
Turbidometric assay
Rheumatoid
arthritis
30
Asemi Z, 2011 [40] Iran 35 (100%)
Prospective, randomized,
single-blinded clinical trial
Probiotic yogurt enriched with
Lactobacillus acidophilus and
Bifidobacterium animalis
Orally 9 weeks
Test: 24.2;
Control: 25.7
Enzyme-linked
immunosorbent
assay (ELISA)
Healthy 37
Asemi Z, 2013 [47] Iran 54 (70%)
Randomized
double-blinded controlled
clinical trial
Lactobacillus acidophilus (2 × 109 CFU),
L. casei (7 × 109 CFU), L. rhamnosus
(1.5 × 109 CFU), L. bulgaricus
(2 × 108 CFU), Bifidobacterium breve
(2 × 1010 CFU), B. longum
(7 × 109 CFU),
Streptococcus thermophilus
(1.5 × 109 CFU)
Orally 8 weeks
Test: 52.59;
Control: 50.51
ELISA
Diabetic
patients
54
Gobel R, 2012 [48] Denmark
50 (Test: 52%;
Control: 59.2)
Double-blinded, randomized,
placebo controlled
intervention study
L. salivarius (1010 CFU) Orally 12 weeks 12–15
Specific
high-sensitivity
CRP
Obese 50
Hattakka K, 2003 [26] Finland
21 (Test: 100%;
Control: 61.5%)
Randomized, double-blind,
placebo-controlled study Lactobacillus rhamnosus, 5 × 10
9 CFU Orally 12 weeks
Test: 50;
Control: 53
——-
Rheumatoid
arthritis
21
Jenks K, 2010 [8] New Zealand
62 (Test: 41%;
Control: 32%)
Randomized
controlled trial
Streptococcus salivarius, Bifidobacterium
lactis, and Lactobacillus acidophilus
Orally 12 weeks
Test: 45.5;
Control: 41.1
ELISA Spondyloarthritis 63
Kajander K, 2007 [41] Finland
86 (Test: 5%;
Control: 91%)
Randomized double-blind,
placebo-controlled,
L. rhamnosus GG, L. rhamnosus,
P. freudenreichii ssp. shermanii JS,
107 CFU
Orally 5 months
Test: 50;
Control: 46
Particle-enhanced
immunoturbidimetric
assay
Irritable bowel
syndrome
patients
86
Leber B, 2012 [49] Austria
30 (Test: 30.7%;
Control: 40%)
An open label, randomized
pilot study L. casei Shirota, 6.5 × 10
9 CFU Orally 3 months
Test: 51.5;
Control: 54.5
—–
Metabolic
syndrome
28
Mc Naught C, 2002 [50] Sweden
130 (Test: 39%;
Control: 44.6%)
Prospective and
randomized Lactobacillus plantarum, 5 × 10
7 CFU Orally 2 weeks
Test: 68;
Control: 69
—– Surgical patients 129
Natarajan R, 2014 [45] USA 41 (16.7%)
Randomized, double-blind,
placebo-controlled
crossover study
Renadyl Orally 6 months 29–79 —–
End-stage renal
disease
—–
Ozkan T, 2007 [42] Turkey 27 (44.4%) Prospectively Saccharomyces boulardii Orally 7 days
6 months to 10
years
ELISA Healthy 27
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Table 1. Cont.
First Author, Reference Country
Total Sample
Size (% Female)
Study Design Probiotics Features
Delivery
Method
Duration
(Weeks)
Age (Years)
C-reactive Protein
(CRP) Assay
Background
Disease
Sample Size
Rajkumar H, 2014 [51] India 30 (53.8%)
A randomized controlled
single-blind pilot study Lactobacillus salivarius, 2 × 10
9 CFU Orally 6 weeks 20–25 dbc-hs Krishgen Healthy 45
Rajkumar H, 2014 [52] India 40 (50%)
A randomized,
controlled trial
Lyophilized Bifidobacteria, Lactobacilli,
and Streptococcus thermophilus,
112.5 × 109 CFU
Orally 6 weeks 40–60 dbc-hs Krishgen Healthy 60
Ranganathan N, 2009 [53] Canada 16 (30.7%) Pilot scale trial
L. acidophilus B. longum and
S. thermophilus, 1.5 × 1010 CFU
Orally 6 months 54 —–
Chronic kidney
disease
16
Sharma B, 2011 [44] India
50 (Test: 57.6%;
Control: 50%)
A double-blind
randomized
placebo-controlled trial
Lactobacillus acidophilus,
Bifidobacterium longus,
Bifidobacterium bifidum, and
Bifidobacterium infantalis
Oral,
nasojejunal,
alternatively,
nasogastric
7 days
Test: 40.19;
Control: 41
ELISA Acute pancreatitis 50
Stiksrud B, 2015 [54] Norway
24 (Test: 28.6%;
Control: 100%)
Randomized in a
double-blind
Lactobacillus rhamnosus,
Bifidobacterium animalis subsp. lactis
and Lactobacillus acidophilus La-5,
108 CFU
Orally 8 weeks
Test: 50.3;
Control: 52.5
—–
Patients on
antiretroviral
therapy
32
Tan M, 2011 [46] China
52 (Test: 26.9%;
Control: 19.2%)
A prospective, randomized
pilot study
Bifidobacterium longum, Lactobacillus
bulgaricus, and Streptococcus
thermophilus, 109 CFU
nasogastric
tube
21 days
Test: 40.5;
Control: 40.8
ELISA
Traumatic brain
injury
26
Valentini L, 2015 [43]
France,
Germany, Italy
62 (53.2%)
Randomized
controlled trial
Bifidobacterium infantis,
Bifidobacterium longum,
Bifidobacterium breve,
Lactobacillus acidophilus,
Lactobacillus delbrückii ssp.
bulgaricus, Lactobacillus paracasei,
Lactobacillus plantarum
Orally 8 weeks 65–85 ELISA Healthy 62
Villar Garcia J, 2015 [55] Spain
44 (Test: 9.1%;
Control: 22.7%)
A single-center,
randomized, double-blind,
placebo-controlled
pilot study
S. boulardii, 6 × 107 CFU Orally 12 weeks
Test: 49.45;
Control: 45.5
Immulite
chemiluminescent
immunometric
assay
HIV-1–infected
patients with
virologic
suppression
44
Zarrati M, 2014 [56] Iran 50 (68%)
Randomized double-blind
controlled clinical trial
Lactobacillus acidophilus,
Lactobacillus casei,
Bifidobacterium lactis, 108 CFU
Orally 8 weeks 20–50 —–
Overweight and
obese individuals
75
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Table 2. Effect of probiotic administration on the other inflammatory, anti-inflammatory, lipid profile
and glycemia measurements.
Factors Results of the Pooled Estimate
IL10 −1.65 pg/dL, (95% CI −3.45 to 0.14)
TNF-α −0.45 pg/mL, (95% CI −1.38 to 0.48)
IL1β −1.07 pg/dL, (95% CI −1.55 to −0.59)
TG −0.92 mg/dL, (95% CI −1.22 to −0.62)
TC −0.58 mg/dL, (95% CI −0.84 to −0.32)
LDL −1.36 mg/dL, (95% CI −1.70 to −1.02)
HDL 0.51 mg/dL, (95% CI 0.19 to 0.83)
FBG −0.75 mg/dL, (95% CI −1.11 to −0.38)
IL10, interlukin 10; TNF-α, tumor necrosis factor alpha; IL1β, interleukin 1β; TG, triglycerides;
TC, total cholesterol; LDL, low density lipoproteins; HDL, high density lipoproteins; FBG, fasting blood glucose.
3.6. Publication Bias
Visual inspection of funnel plot asymmetry indicated a potential publication bias for the
comparison of plasma CRP levels between probiotic administered groups and placebo groups
(Figure 3). Further, the presence of publication bias was suggested by Egger’s linear regression
(intercept = −9.39, standard error = 3.04; 95% CI = −15.80, 2.99, t = 3.08, degree of freedom
(df ) = 18.00, two-tailed p < 0.001) but Begg’s rank correlation test was not indicative of a publication bias
(Kendall’s Tau with continuity correction = −0.28, z = 1.75, two-tailed p = 0.079). After adjustment of
effect size for potential publication bias using the ‘trim and fill’ correction, no potentially missing study
was imputed in the funnel plot (WMD 1.35 mg/dL, 95% CI −2.15 to −0.55) (Figure 4). The ‘fail-safe
N’ test showed that 1003 studies would be needed to bring the WMD down to a non-significant
(p > 0.05) value.
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Figure 4. Trim and fill method was used to impute for potentially missing studies, no potentially
missing study was imputed in funnel plot. Open circles represent observed published studies; open
diamond represents observed effect size; closed diamond represents imputed effect size.
4. Discussion
This meta-analysis suggests that probiotic administration may reduce serum CRP levels. A strong
relationship has been reported between the level of oxidative stress and inflammatory markers and
risk of cardiovascular disease [57,58]. Along with other pathophysiological complications of oxidative
stress, inflammation is associated with insulin resistance. This, in turn, causes diminished glucose
uptake and disposal in peripheral tissues and increased glucose production in the liver [57,58].
Similar to our findings, Asemi et al. demonstrated that consumption of probiotic supplements
results in a significant reduction in serum hs-CRP levels compared with placebo [24]. Moreover,
consumption of a combination of L. casei, B. breve, and prebiotic galacto oligosaccharides [59] as
well as B. longum [60] in immunocompromised patients has been found to decrease serum hs-CRP
levels in only three of the studies that measured hs-CRP. The initial hs-CRP levels were well below
the cutoff of ≥10 mg/L as an indicator of acute inflammation (Supplementary Materials Table S1).
The anti-inflammatory effect of Lactobacillus reuteri and the anti-oxidant and anti-inflammatory effects
of L. plantarum are among studies in which the impact of probiotics on the management of diabetes
has been investigated [61]. In animal studies, Yadav et al. stated that the feeding of probiotic dahi
(yogurt) containing 108 strains of L. acidophilus and L. casei delayed the onset of glucose intolerance,
hyperglycemia, hyperinsulinemia, dyslipidemia, and oxidative stress in fructose-induced type 2
diabetes rats.
Several mechanisms are suggested to explain the effects of probiotics on serum hs-CRP levels
including the effects of short-chain fatty acids that are produced from probiotics in the colon [24,25].
This consequently results in decreased enzymatic synthesis of hepatic hs-CRP. The decreased serum
hs-CRP levels might also result from decreased expression of IL-6. It has also been suggested
that decreased inflammation and oxidative stress by probiotics consumption might be due to
their effects on increasing glutathione (GSH) levels, scavenging superoxide and hydroxyl radicals,
decreasing expression of interleukin-6 (IL-6) in adipocytes, and decreasing adiposity [24,25]. In contrast,
Hattakka et al. have reported that probiotic supplementation had no significant effect on the serum
concentrations of several cytokines [6,26]. Furthermore, Shoaei et al. reported an 8-week multispecies
probiotics supplementation had a non-significant beneficial effect on pancreatic β-cell function and
hs-CRP in polycystic ovary syndrome (PCOS) patients [22]. The disagreement between the results
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of the previously conducted clinical trials may be in part due to the different strains of probiotics
and dose of the probiotic administered. Some in vitro studies have indicated that certain effects are
seen only when low doses of probiotics are applied, and that high doses may cause opposite effects
compared to those obtained at lower doses [6,62]. Several human studies have also recommended
that lower doses of probiotics may be more effective and improve cellular immunity to the preferred
extent [63].
Several mechanisms have been suggested concerning the impact of probiotics on inflammation
and inflammatory factors. Probiotics can prevent or repair the ‘leaky’ epithelial barriers and indirectly
affect the inflammatory response by opposing the source of pro-inflammatory impetuses associated
with low-grade endotoxemia [2,64]. Further, probiotics increase production of short-chain fatty acids
(SCFA) such as butyrate which has an anti-inflammatory function. They also enhance synthesis
of antimicrobial peptides that influence inflammation resolution pathways in the mucosa [64–66].
Probiotics can act as ligands for innate immune system receptors and directly affect pro-inflammatory
pathways. They also stimulate the differentiation and activity of immune cells such as dendritic cells
and T-cells and consequently enhance production of some regulatory cytokines [65,66].
As an important point, we also need to consider the effect size for each of the outcomes of interest
and compare it with the normal range of the value to understand the magnitude of changes.
There are some potential limitations in our analysis that need to be addressed. First, as
with any meta-analysis, internal validity relies on the quality of individual studies. Most of the
included studies had relatively medium sample sizes, potentially leading to overestimation of
treatment effects; smaller trials might be methodologically less robust and more prone to report
larger effect sizes [67,68]. Another limitation is the variability in the type of CRP assays across
the studies under this review. Only three of these have applied a high-sensitivity (hs) CRP assay
(Supplementary Materails Table S1). Although the hs-CRP values in those studies were ≥10 mg/L as
the cut-off for acute inflammation, our results should be interpreted with caution. The studies that met
the inclusion criteria and were analyzed are also heterogeneous regarding the main health outcomes
under the studies and the type of CRP assays. Only three of them applied a high-sensitivity CRP assay
(Supplementary Materials Table S1). Hence, our results should be interpreted with caution.
5. Conclusions
Our meta-analysis suggests consuming probiotics appears to be beneficial by decreasing some
inflammatory cytokines and biomarkers that may play a role in the development of cardiovascular
disease and type 2 diabetes mellitus. More clinical trials with longer duration and larger sample sizes
and consistency in terms of the laboratory measurements are still needed to explore the exact dose
and strains of probiotic supplement in each specific disease. Although we found a protective effect of
probiotics on CRP, these results should be interpreted with caution due to the (i) heterogeneity of health
outcomes; (ii) variability in the assays under the studies included in this review; and (iii) complexity of
the pathways in which gut microbiota play a role in the inflammation and anti-inflammation balance
in different diseases.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/9/1/20/s1,
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assessment of the included studies according to the Cochrane guidelines.
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